Prostaglandin F2α Tromethamine Injection

Basic Product Information

Concentration:

10ml:50mg; 30ml:150mg

5 mg/mL (each milliliter contains 5 mg of

prostaglandin F2α [PGF2α] as the

tromethamine salt, a stable, bioavailable formulation).

Core Mechanism:

Exerts two key effects in cows:

luteolysis (breaks down the corpus luteum,

 a progesterone-secreting ovarian structure) to regulate reproductive cycles;

uterotonic activity (stimulates uterine contractions) to support uterine health and parturition.

Key Advantage: 

The 5 mg/mL concentration allows flexible, precise dosing (ideal for adjusting volumes based on cow size or specific therapeutic needs, reducing the risk of over/under-dosing).

Indications

This formulation is used to manage reproductive disorders and support uterine health in cows, leveraging its luteolytic and uterotonic properties:

Reproductive Cycle Regulation

Estrus synchronization:

Induces uniform estrus in cycling cows, simplifying timed artificial insemination (AI) and herd breeding management (eliminates the need for frequent estrus checks).

Estrus induction in anestrous cows:

Stimulates return to cyclicity in cows with delayed post-calving estrus or inactive ovaries (caused by residual luteal tissue).

Parturition Management

Induction of parturition: 

Initiates labor in late-gestation cows (10–14 days before the expected due date) for scheduled calving (e.g., aligning with labor staff availability) or to resolve prolonged gestation.

Luteal Disorder Treatment

Resolution of persistent corpus luteum (PCL):

Treats PCL—a major cause of infertility—by breaking down non-functional, long-lasting luteal tissue, restoring normal estrous cycles.

Uterine Health Support

Adjunctive treatment for uterine disorders:

Promotes uterine contractions to expel abnormal contents in cases of:

Pyometra (pus accumulation in the uterus).

Endometritis (inflammation of the uterine lining).

Retained fetal membranes (aids in expulsion within 24–48 hours post-calving).

Dosage & Administration

Route of Administration

Intramuscular (IM) injection (preferred):

Ensures rapid, consistent absorption of PGF2α, delivering reliable therapeutic effects.

Subcutaneous (SC) injection (alternative): Permitted for emaciated cows or those with sensitive muscle tissue (slower absorption but equivalent efficacy).

Indication	Target PGF2α Dose (per adult cow)	Injection Volume (5 mg/mL)	Timing & Key Notes
Estrus synchronization	25–50 mg	5–10 mL	Estrus occurs 48–72 hours post-injection; time AI 12–24 hours after estrus onset.
Induction of parturition	25–50 mg	5–10 mL	Administer 10–14 days pre-due date (≥260 days of gestation). Calving occurs within 24–72 hours; do not use earlier (risk of premature calves).
Persistent corpus luteum	25–50 mg	5–10 mL	Recheck via ultrasound 7 days post-injection; repeat dose only if PCL persists.
Uterine disorders (pyometra/endometritis)	25–50 mg	5–10 mL	Repeat after 10–14 days if clinical signs (e.g., yellow/brown discharge) persist. Combine with antibiotics for severe infections.

Clinical Trial Data

Efficacy of the 5 mg/mL injection has been validated in randomized controlled trials (RCTs) involving dairy and beef cows, focusing on its dosing flexibility and safety:

Trial 1: Estrus Synchronization (n=200 Cycling Dairy Cows)

Study Design:

Cows were split into two groups:

Treatment group:

5–10 mL (25–50 mg) of 5 mg/mL PGF2α (IM) once.

Control group: No injection.

Key Results:

Estrus uniformity: 

86% of treated cows exhibited estrus within 48–72 hours, vs. 28% of control cows (scattered estrus over 14 days).

Conception rate:

63% of treated cows conceived after timed AI, comparable to the control group’s 60% (no negative impact on fertility).

Trial 2: Parturition Induction (n=150 Late-Gestation Cows)

Study Design:

Cows (≥260 days gestation) received 5–10 mL (25–50 mg) of 5 mg/mL PGF2α (IM) or a placebo.

Key Results:

Calving timing:

91% of treated cows calved within 24–72 hours, vs. 17% of placebo cows (natural calving over 10 days).

Calf health:

Dystocia rate (7% in treated vs. 6% in control) and neonatal mortality (2.7% vs. 2.5%) were not significantly different, confirming safety.

Trial 3: Persistent Corpus Luteum (PCL) Treatment (n=80 Infertile Cows)

Study Design:

Cows with ultrasound-confirmed PCL received 5–10 mL (25–50 mg) of 5 mg/mL PGF2α (IM) or no treatment.

Key Results:

PCL resolution: 89% of treated cows had luteal breakdown within 7 days, vs. 11% of control cows.

Cycle recovery:

77% of treated cows resumed normal estrous cycles within 3 weeks, vs. 14% of control cows.

Storage: Store at 2°C – 25°C (35.6°F – 77°F).

Package: 10ml/bottle; 30ml/bottle